甘精胰岛素注射液质量状况评价与研究

doi:10.19803/j.1672-8629.20230460

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (6): 644-650.
DOI: 10.19803/j.1672-8629.20230460

甘精胰岛素注射液质量状况评价与研究

丁晓丽, 胡馨月^△, 王雪蕾, 孙悦, 李晶, 张慧, 梁成罡^*, 王岩^#

中国食品药品检定研究院化学药品检定所,国家药品监督管理局化学药品质量研究与评价重点实验室,北京 102629

收稿日期:2023-07-17 出版日期:2024-06-15 发布日期:2024-06-18
通讯作者: ^*梁成罡,男,博士,研究员,激素与生物技术药物质量控制研究。E-mail：liangchenggang@nifdc.org.cn; ^#为共同通信作者。
作者简介:丁晓丽,女,硕士,副研究员,胰岛素类药物质量控制研究。^△为并列第一作者。
基金资助:
国家重点研发计划（2021YFF0600804）

Quality evaluation of insulin glargine injections

DING Xiaoli, HU Xinyue^△, WANG Xuelei, SUN Yue, LI Jing, ZHANG Hui, Liang Chenggang^*, WANG Yan^#

National Institutes for Food and Drug Control, Institute for Chemical Drug Control, NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing 102629, China

Received:2023-07-17 Online:2024-06-15 Published:2024-06-18

摘要/Abstract

摘要： 目的评价甘精胰岛素注射液的质量现状及存在问题,对现行质量标准的科学性及合理性进行评估,为其安全评价及安全监管提供参考。方法对甘精胰岛素注射液进行国家评价性抽检,采用法定标准方法对抽检样品的有关物质及含量测定项目进行检验,并对不同企业的样品进行了稳定性研究及样品使用期有关物质增长情况研究,采用LC-MS方法对含量较高的有关物质进行了结构确认,根据研究结果对企业标准及《中华人民共和国药典》（2020年版）各论中有关物质的限度规定进行了科学性及合理性评估。结果按照法定标准检验,48批次的甘精胰岛素注射液样品有关物质及含量测定结果均合格,合格率100%。稳定性研究发现,部分企业样品有关物质的数量及含量结果偏高;样品使用期有关物质增长情况研究发现,部分企业样品中最大有关物质的含量有超出企业质量标准限度规定的风险。结论甘精胰岛素注射液总体质量较好。建议企业考察产品在货架期及使用期（尤其是近效期产品）的有关物质的增长情况,并参考《中华人民共和国药典》（2020年版）甘精胰岛素注射液各论,科学合理地制定标准限度规定。

关键词: 甘精胰岛素, 注射液, 评价性抽检, 质量评价, 有关物质, 药品使用期, 稳定性研究, 质量标准, 标准限度

Abstract: Objective To evaluate the quality of and problems with insulin glargine injections, and study the validity and rationality of drug specifications so as to provide reference for evaluation and supervision of safety. Methods Insulin glargine injections were sampled and evaluated nationwide. The related substances and contents of the samples were tested using the stipulated standard method. The stability of injections and the increase of related substances of injections in usewere tested via exploratory research, and the structures of main related substances were confirmed by LC-MS/MS. According to the results, the limits of related substances specified in enterprise standards and the current Chinese pharmacopoeia standard were evaluated. Results The qualified rate of 48 batches of insulin glargine injections was 100%. Exploratory research showed that the number or contents of related substances in some of the insulin glargine injections were higher, and the contents of maximum related substances in some of the injections were at risk of exceeding the limit of enterprise standards. Conclusion The overall quality of insulin glargine injections is good. Related enterprises should formulate rational and precise limits of related substances in line with the Chinese pharmacopoeia by investigating the increase of relevant substances on the shelf or in use (especially near-effect products).

Key words: insulin glargine, injection, sampling inspection, quality evaluation, related substance, in-use period, stability study, standard, limit of related substances

中图分类号:

R977.15

丁晓丽, 胡馨月, 王雪蕾, 孙悦, 李晶, 张慧, 梁成罡, 王岩. 甘精胰岛素注射液质量状况评价与研究[J]. 中国药物警戒, 2024, 21(6): 644-650.

DING Xiaoli, HU Xinyue, WANG Xuelei, SUN Yue, LI Jing, ZHANG Hui, Liang Chenggang, WANG Yan. Quality evaluation of insulin glargine injections[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 644-650.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20230460

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I6/644

参考文献

[1] ZHAO XJ, YANG LX, GAN DC, et al.Research progress on treatment of glucose and lipid metabolism disorders in type 2 diabetes mellitus with traditional Chinese medicine[J]. Asia-Pacific Traditional Medicine(亚太传统医药), 2023, 7(19): 234-237.
[2] HUANG H, WANG HF, ZHU DL, et al.Efficacy and safety of insulin glargine injection (HS004) compared with Lantus in diabetes: a phase III multicenter, randomized, open-label, parallel, active-controlled clinical trial[J]. Chin J Clin Res(中国临床研究), 2023, 36(3): 391-397.
[3] JI LN, ZHANG PH, ZHU DS, et al.Observational registry of basal insulin with oral antihyperglycaemic drugs: real-life use of basal insulin in China[J]. Diabetes Obes Metab, 2017, 19(6): 822-830.
[4] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China, Volume III(中华人民共和国药典三部)[M]. Beijing: China Medical Science Press, 2020: 390.
[5] LI J, LIANG CG, ZHANG H, et al.Structure identification and quality analysis of relative impurities of recombinant insulin glargine[J]. Chin Pharm J(中国药学杂志), 2008, 43(20): 1588-1592.
[6] WANG LY, YANG HM,LI J, et al.Research of peptide mapping method for insulin glargine[J]. Lett Biotechnol(生物技术通讯), 2018, 29(5): 667-676.
[7] CHEN LJ,YANG XH,FENG Y, et al.Clinical application of insulin aspartate combined with insulin glargine in patients with type 2 diabetes mellitus[J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine(深圳中西医结合杂志), 2022, 32(23): 119-121.
[8] SEMLITSCH T, ENGLER J, SIEBENHOFER A, et al. (Ultra-) long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes medllitus[J]. Cochrane Database Syst Rev, 2020, 11(11): CD005613.
[9] YIN HJ, YU SS, YIN MS, et al.Research progress and safety characteristics of recombinant human insulin analogues[J]. Chinese Journal of New Drugs(中国新药杂志), 2018, 27(21): 2578-2583.
[10] HU XY, SUN Y, LIANG CG, et al.Measurement of primary structure of fatty acid modified GLP-1 analogues by LC-MS/MS[J]. Chin Med Biotechnol(中国医药生物技术), 2024, 18(6): 540-549.
[11] BRANG J. LANGKJAER L.Chemical Stability of insulin.3.Influence of excipients, formulation and pH[J]. Acta Pharm. Nord, 1992, 4(3): 149-158.
[12] BRANGE J.Chemical Stability of Insulin. 4. Mechanisms and kinetics of chemical transformations in pharmaceutical formulation[J]. Acta Pharm Nord, 1992, 4(4): 209-222.
[13] PETERS B, TROUT BL.Asparagine deamidation: pH-dependent mechanism from density functional theory[J]. Biochemistry, 2006, 45(16): 5384-5388.
[14] ROBINSON NE, ROBINSON AB.Molecular clocks[J]. Proc Natl Acad Sci USA, 2001, 98(3): 944-950.
[15] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China, Volume IV(中华人民共和国药典四部)[M]. Beijing: China Medical Science Press, 2020: 457.
[16] DING XL, CHEN Y, LIANG CG, et al.Determination of related substances in insulin glargine injection[J]. Chin J Pharm Anal(药物分析杂志), 2022,42(1): 21-30.
[17] SUN RX, LUO L, CHI H, et al.“Top-down”proteomics - large-scale identification of protein variants[J]. Progress in Biochemistry and Biophysics(生物化学与生物物理进展)2015, 42(2):101-105.
[18] ZHAO LY, ZHANG YJ, QIAN XH.Advances in N terminal sequencing of proteins and peptides[J]. Chin Med Biotechnol(中国医药生物技术), 2008, 3(3): 214-219.
[19] WEN XM, LI Y, LU J, et al.Application progress of tandem mass spectrometry in the structural confirmation of synthetic polypeptide drugs[J]. Chinese pharmacy(中国药房), 2019, 30(20): 2876-2880.
[20] WIESE H, KUHLMANN K, WIESE S, et al.Comparison of alternative MS/MS and bioinformatics approaches for confident phosphorylation site localization[J]. J Proteome Res, 2014, 13: 1128-1137.

甘精胰岛素注射液质量状况评价与研究

Quality evaluation of insulin glargine injections

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	魏曼莉, 吕林艳, 郑志远, 尹纪业, 麦志雄. 血栓通注射液临床前遗传毒性研究[J]. 中国药物警戒, 2024, 21(9): 1014-1018.
[2]	刘婷, 曹忠强, 何文佳, 袁秀丽, 陈泽彬, 李学娟. 培门冬酶注射液致急性重症胰腺炎1例分析[J]. 中国药物警戒, 2024, 21(9): 1075-1077.
[3]	刘毅, 刘晓强, 姚晓, 李选堂, 郭贤辉, 耿颖, 裴宇盛. 溴己新注射剂临床配伍用药研究[J]. 中国药物警戒, 2024, 21(8): 884-887.
[4]	孙莉, 谢彬, 徐艳琴. 中药缓控释制剂研究进展[J]. 中国药物警戒, 2024, 21(8): 949-954.
[5]	孙悦, 胡馨月, 李晶, 张伟, 丁晓丽, 张慧, 梁成罡. 去氨加压素片及其注射液质量评价[J]. 中国药物警戒, 2024, 21(6): 632-637.
[6]	张孝明, 吕萍, 胡馨月, 丁晓丽, 李晶, 梁成罡. 酶联免疫法测定甘精胰岛素中单链前体残留研究[J]. 中国药物警戒, 2024, 21(3): 290-294.
[7]	陈杰, 张斌, 赵俊, 张传洲. 托珠单抗注射液致过敏性休克1例分析[J]. 中国药物警戒, 2024, 21(3): 349-351.
[8]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[9]	江楠, 王琨, 张钢平, 邢瑞敏, 王海叶. 异甘草酸镁注射液致过敏性休克1例分析[J]. 中国药物警戒, 2024, 21(11): 1309-1311.
[10]	李耀磊, 金红宇, 魏锋, 马双成. 前胡的一般概况及质量形成因素浅析[J]. 中国药物警戒, 2024, 21(11): 1315-1320.
[11]	巨康璐, 常瑛, 刘振国. 缩宫素注射液致严重过敏样反应1例分析[J]. 中国药物警戒, 2024, 21(10): 1169-1171.
[12]	刘猛, 方可, 严家菊, 刘梦, 何曼云, 魏良兵. 帕米膦酸二钠葡萄糖注射液致过敏性休克 1 例分析[J]. 中国药物警戒, 2024, 21(10): 1172-1174.
[13]	史卜文, 李利寻, 谢雁鸣, 王志飞, 王淇. 真实世界喜炎平注射液治疗3846例细菌性肠道感染患者临床用药特征分析[J]. 中国药物警戒, 2023, 20(9): 1017-1021.
[14]	孟康康, 刘赛月. 辅酶Q10注射剂上市后安全性分析[J]. 中国药物警戒, 2023, 20(7): 795-798.
[15]	秦桂兰, 周木子, 冀召帅, 毛乾泰, 艾超. 司美格鲁肽注射液致急性便秘1例分析[J]. 中国药物警戒, 2023, 20(7): 833-835.